`U.S. Patent No. 10,195,214
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_______________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_______________________
`
`TEVA PHARMACEUTICALS USA, INC.,
`Petitioner
`
`v.
`
`CORCEPT THERAPEUTICS, INC.,
`Patent Owner
`_______________________
`
`Case PGR2019-00048
`U.S. Patent No. 10,195,214
`_______________________
`
`DECLARATION OF DANIEL C. WIESNER IN SUPPORT OF
`PATENT OWNER’S MOTION FOR
`PRO HAC VICE ADMISSION UNDER 37 C.F.R. § 42.10(c)
`
`Teva Pharmaceuticals USA, Inc. v. Corcept Therapeutics, Inc.
`PGR2019-00048
`Corcept Ex. 2068
`
`
`
`
`
`
`
`PGR2019-00048
`U.S. Patent No. 10,195,214
`
`I, Daniel C. Wiesner, declare as follows:
`
`1.
`
`I am Of Counsel at the law firm Quinn Emanuel Urquhart & Sullivan, LLP.
`
`I am a member in good standing of the State Bar of New York, and have practiced
`
`patent litigation since 2004.
`
`2.
`
`I have never been suspended or disbarred from practice before any court or
`
`administrative body.
`
`3.
`
`I have never had any application for admission to practice before any court
`
`or administrative body denied.
`
`4.
`
`I have never been the subject of any sanctions or contempt citations imposed
`
`by any court or administrative body.
`
`5.
`
`I have read and will comply with the Office Patent Trial Practice Guide and
`
`the Board’s Rules of Practice for Trials set forth in part 42 of the C.F.R.
`
`6.
`
`I will be subject to the USPTO Code of Professional Responsibility and
`
`disciplinary jurisdiction.
`
`7.
`
`I have previously applied to appear pro hac vice before the Patent and
`
`Trademark Office in Actavis LLC v. Abraxis Bioscience, LLC, IPR2017-01101,
`
`IPR2017-01103, IPR2017-01104 (PTAB), and was admitted.
`
`8.
`
`I have an established familiarity with the subject matter at issue in this Post
`
`Grant Review. Specifically, I have experience representing Corcept Therapeutics,
`
`Inc. (“Corcept”) with respect to the subject matter at issue in this Post Grant
`
`
`
`1
`
`
`
`
`
`
`
`PGR2019-00048
`U.S. Patent No. 10,195,214
`
`Review, including the specific patent and prior art at issue. In addition, I am trial
`
`counsel for Corcept in the patent litigation against Teva concerning the patent
`
`challenged in the petition (Corcept Therapeutics, Inc. v. Teva Pharmaceuticals
`
`USA, Inc. et. al, No. 2:18-cv-03632-SDW-CLW (D.N.J.)).
`
`
`
`
`
`I declare under penalty of perjury that the foregoing is true and correct.
`
`Date: June 16, 2020
`
`/Daniel C. Wiesner/
`
`
`
`
`
`
`
` Daniel C. Wiesner
`
`2
`
`